coumarin has been researched along with Thromboembolism, Venous in 2 studies
2H-chromen-2-one: coumarin derivative
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with active cancer and acute venous thromboembolism (VTE), the low-molecular-weight-heparin (LMWH) dalteparin is more effective than vitamin K antagonist (VKA) in reducing the risk of recurrent venous thromboembolism (rVTE) without increasing the risk of bleeding." | 9.30 | Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. ( Abreu, P; Carrier, M; Feugère, G; Heissler, J; Lee, AYY; Woodruff, S, 2019) |
| "In patients with active cancer and acute venous thromboembolism (VTE), the low-molecular-weight-heparin (LMWH) dalteparin is more effective than vitamin K antagonist (VKA) in reducing the risk of recurrent venous thromboembolism (rVTE) without increasing the risk of bleeding." | 5.30 | Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. ( Abreu, P; Carrier, M; Feugère, G; Heissler, J; Lee, AYY; Woodruff, S, 2019) |
| "By identifying VTE recurrence risk in cancer patients with VTE, we may be able to tailor treatment, improving clinical outcomes while minimizing costs." | 2.77 | Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. ( Carrier, M; Dao, V; Kovacs, MJ; Lazo-Langner, A; Lee, AY; Louzada, ML; Meyer, G; Ramsay, TO; Rodger, MA; Wells, PS; Zhang, J, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Woodruff, S | 1 |
| Lee, AYY | 1 |
| Carrier, M | 2 |
| Feugère, G | 1 |
| Abreu, P | 1 |
| Heissler, J | 1 |
| Louzada, ML | 1 |
| Lazo-Langner, A | 1 |
| Dao, V | 1 |
| Kovacs, MJ | 1 |
| Ramsay, TO | 1 |
| Rodger, MA | 1 |
| Zhang, J | 1 |
| Lee, AY | 1 |
| Meyer, G | 1 |
| Wells, PS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Analysis of Pro-coagulant and Thrombin-generation Markers for the Prediction of Therapeutic Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism: A Pilot Study[NCT01602445] | 700 participants (Anticipated) | Observational | 2012-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for coumarin and Thromboembolism, Venous
| Article | Year |
|---|---|
Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study.
Topics: Aged; Coumarins; Dalteparin; Disease-Free Survival; Female; Hemorrhage; Humans; Male; Middle Aged; N | 2019 |
Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism.
Topics: Anticoagulants; Cohort Studies; Coumarins; Decision Support Techniques; Female; Heparin, Low-Molecul | 2012 |